Rapport Therapeutics, Common Stock Alpha and Beta Analysis
| RAPP Stock | 30.64 0.39 1.29% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Rapport Therapeutics, Common. It also helps investors analyze the systematic and unsystematic risks associated with investing in Rapport Therapeutics, over a specified time horizon. Remember, high Rapport Therapeutics,'s alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Rapport Therapeutics,'s market risk premium analysis include:
Beta 1.42 | Alpha 0.25 | Risk 3.58 | Sharpe Ratio 0.0471 | Expected Return 0.17 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Rapport Therapeutics, Backtesting, Rapport Therapeutics, Valuation, Rapport Therapeutics, Correlation, Rapport Therapeutics, Hype Analysis, Rapport Therapeutics, Volatility, Rapport Therapeutics, History and analyze Rapport Therapeutics, Performance. Rapport Therapeutics, Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Rapport Therapeutics, market risk premium is the additional return an investor will receive from holding Rapport Therapeutics, long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Rapport Therapeutics,. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Rapport Therapeutics,'s performance over market.| α | 0.25 | β | 1.42 |
Rapport Therapeutics, expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Rapport Therapeutics,'s Buy-and-hold return. Our buy-and-hold chart shows how Rapport Therapeutics, performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Rapport Therapeutics, Market Price Analysis
Market price analysis indicators help investors to evaluate how Rapport Therapeutics, stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Rapport Therapeutics, shares will generate the highest return on investment. By understating and applying Rapport Therapeutics, stock market price indicators, traders can identify Rapport Therapeutics, position entry and exit signals to maximize returns.
Rapport Therapeutics, Return and Market Media
The median price of Rapport Therapeutics, for the period between Wed, Oct 1, 2025 and Tue, Dec 30, 2025 is 27.25 with a coefficient of variation of 6.99. The daily time series for the period is distributed with a sample standard deviation of 1.93, arithmetic mean of 27.57, and mean deviation of 1.67. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Weiss Ratings Reaffirms Sell Rating for Rapport Therapeutics | 10/09/2025 |
2 | Disposition of 755 shares by Ceesay Abraham of Rapport Therapeutics, at 26.1721 subject to Rule 16b-3 | 10/15/2025 |
3 | Does Rapport Therapeutics Rising Losses and Improving Per-Share Results Reveal a Shift in RAPPs Strategy | 11/17/2025 |
4 | Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeti... | 11/25/2025 |
5 | Disposition of 5000 shares by Cheryl Gault of Rapport Therapeutics, at 1.8 subject to Rule 16b-3 | 11/26/2025 |
6 | Wall Street Analysts See a 74.99 percent Upside in Rapport Therapeutics, Inc. Can the Stock Really Move This High | 11/28/2025 |
7 | Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219s Clinical Response in Patients with Focal O... | 12/05/2025 |
8 | Rapport Therapeutics, Inc. Is Up 9.03 percent in One Week What You Should Know | 12/08/2025 |
9 | Rapport Therapeutics Shapes Focused Clinical Neuroscience Programs - Kalkine Media | 12/12/2025 |
10 | Rapport Therapeutics Upgraded at Wall Street Zen | 12/17/2025 |
11 | How RAP-219 Phase 2a Data and 2026 Phase 3 Plans At Rapport Therapeutics Has Changed Its Investment Story | 12/19/2025 |
12 | Rapport Therapeutics Valuation Check After Joining the SP Pharmaceuticals Select Industry Index | 12/23/2025 |
About Rapport Therapeutics, Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Rapport or other stocks. Alpha measures the amount that position in Rapport Therapeutics, has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2010 | 2023 | 2024 | 2025 (projected) | Current Ratio | 18.8 | 17.14 | 35.34 | 19.01 | Net Debt To EBITDA | 2.0 | 1.96 | 0.71 | 0.68 |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Rapport Therapeutics, in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Rapport Therapeutics,'s short interest history, or implied volatility extrapolated from Rapport Therapeutics, options trading.
Build Portfolio with Rapport Therapeutics,
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Rapport Stock Analysis
When running Rapport Therapeutics,'s price analysis, check to measure Rapport Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rapport Therapeutics, is operating at the current time. Most of Rapport Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Rapport Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rapport Therapeutics,'s price. Additionally, you may evaluate how the addition of Rapport Therapeutics, to your portfolios can decrease your overall portfolio volatility.